After a painful stumble, AstraZeneca gets top checkpoint cancer program back on track
The FDA has lifted the partial hold it dropped on AstraZeneca’s top pipeline drug durvalumab a month ago, allowing investigators to resume recruiting patients with head and neck cancer for two key late-stage trials.
Playing catch-up with Merck, Bristol-Myers Squibb and Roche, the partial hold in October rattled investors, raising a red flag that dragged the pharma giant a bit further behind in one of the most competitive R&D fields in biopharma. But regulators agreed to get the studies back on track with no change in protocols, evidently satisfied that the bleeding episodes that triggered the hold posed no special threat to others.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
